TCI Wealth Advisors, Inc. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
TCI Wealth Advisors, Inc. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$150
+28.2%
1000.0%0.00%
Q4 2022$1171000.0%0.00%
Q3 2022$0100
-50.0%
0.00%
Q2 2022$02000.0%0.00%
Q1 2022$0
-100.0%
200
-90.6%
0.00%
-100.0%
Q4 2021$5,0002,1370.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders